Incyte ' s Jakafi Gets FDA Approval to Treat Graft vs Host Disease Incyte ' s Jakafi Gets FDA Approval to Treat Graft vs Host Disease

The U.S. Food and Drug Administration on Friday approved Incyte Corp ' s treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Family Medicine/Primary Care News Source Type: news